Alamar Biosciences, a precision proteomics company focused on early disease detection, has announced a strategic collaboration with SciLifeLab, Sweden's national center for molecular biosciences, to advance translational proteomics and accelerate biomarker discovery.
The partnership brings together Alamar's proprietary NULISA technology and ARGO HT system, which offer ultra-sensitive, multiplexed protein analysis from biofluids, with SciLifeLab's extensive proteomics capabilities and data resources. These resources include the Human Protein Atlas, a comprehensive research program that maps the human proteome across tissues and cell types.
Technology Integration for Enhanced Sensitivity
The collaboration aims to leverage the combined technological capabilities to achieve unprecedented levels of protein detection sensitivity. Alamar's NULISA Platform and ARGO HT System work in conjunction with genomics advances to achieve single digit attomolar detection sensitivity, which the company states "greatly surpasses the most sensitive protein detection technology on the market today."
"We are thrilled to partner with SciLifeLab in this important work," stated Dr. Yuling Luo, Chairman, Founder & CEO of Alamar Biosciences. "Our combined technologies will provide comprehensive data on protein expression and localization, which will be instrumental in validating signatures discovered using the NULISA platform."
Research Infrastructure and Capabilities
SciLifeLab operates as a joint initiative between four major Swedish institutions: Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University, and Uppsala University. The organization provides unique research infrastructure and data resources while fostering collaboration between academia, healthcare, and industry sectors.
Professor Jochen Schwenk, SciLifeLab Group Leader and Platform Scientific Director of Proteomics, emphasized the strategic fit of the partnership. "SciLifeLab's expertise in affinity proteomics, combined with our national infrastructure and partnership with National Genomics Infrastructure, makes this a natural environment for a cutting-edge technology like the ARGO HT System," he said. "We look forward to enabling new levels of sensitivity, scalability, and integration in biomarker discovery."
Organizational Scale and Impact
SciLifeLab operates with more than 40 national infrastructure units and approximately 1,500 researchers, positioning it as a leading hub for life science innovation and translational research. The organization's extensive network and resources are expected to complement Alamar's precision proteomics technology platform.
The collaboration represents a significant step toward developing early diagnostic tools through enhanced understanding of disease biology. By combining ultra-sensitive protein detection capabilities with comprehensive proteome mapping resources, the partnership aims to accelerate the discovery and validation of biomarkers that could enable earlier disease detection and intervention.
